New research shows that a substantial proportion of patients with acute disseminated encephalomyelitis have serum antibodies against myelin oligodendrocyte glycoprotein. The relationship between these antibodies and other demyelinating disorders such as multiple sclerosis, however, remains unclear.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Antibody-mediated biorecognition of myelin oligodendrocyte glycoprotein: computational evidence of demyelination-related epitopes
Scientific Reports Open Access 14 February 2019
Access options
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Lalive, P. et al. Highly reactive anti-myelin oligodendrocyte glycoprotein antibodies differentiate demyelinating diseases from viral encephalitis in children. Mult. Scler. 17, 297–302 (2011).
Di Pauli, F. et al. Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases. Clin. Immunol. 138, 247–254 (2011).
Selter, R. C. et al. Antibody responses to EBV and native MOG in pediatric inflammatory demyelinating CNS diseases. Neurology 74, 1711–1715 (2010).
Brilot, F. et al. Antibodies to native myelin oligodendrocyte glycoprotein in children with inflammatory demyelinating central nervous system disease. Ann. Neurol. 66, 833–842 (2009).
O'Connor, K. C. et al. Self-antigen tetramers discriminate between myelin autoantibodies to native or denatured protein. Nat. Med. 13, 211–217 (2007).
McLaughlin, K. A. et al. Age-dependent B cell autoimmunity to a myelin surface antigen in pediatric multiple sclerosis. J. Immunol. 183, 4067–4076 (2009).
Brehm, U., Piddlesden, S. J., Gardinier, M. V. & Linington, C. Epitope specificity of demyelinating monoclonal autoantibodies directed against the human myelin oligodendrocyte glycoprotein (MOG). J. Neuroimmunol. 97, 9–15 (1999).
Weissert, R. et al. MHC haplotype-dependent regulation of MOG-induced EAE in rats. J. Clin. Invest. 102, 1265–1273 (1998).
Wallström, E. et al. Increased reactivity to myelin oligodendrocyte glycoprotein peptides and epitope mapping in HLA DR2(15)+ multiple sclerosis. Eur. J. Immunol. 28, 3329–3335 (1998).
Hauser, S. L. et al. B-cell depletion with rituximab in relapsing–remitting multiple sclerosis. N. Engl. J. Med. 358, 676–688 (2008).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Olsson, T. Roles of anti-MOG antibodies in demyelinating diseases. Nat Rev Neurol 7, 248–249 (2011). https://doi.org/10.1038/nrneurol.2011.45
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneurol.2011.45
This article is cited by
-
Antibody-mediated biorecognition of myelin oligodendrocyte glycoprotein: computational evidence of demyelination-related epitopes
Scientific Reports (2019)
-
Anti-MOG antibodies are under polygenic regulation with the most significant control coming from the C-type lectin-like gene locus
Genes & Immunity (2013)
